The Phase 3 clinical trial (NCT06131437) for CagriSema, an investigational medicine combining Cagrilintide B and Semaglutide I, reached its primary completion on December 8, 2025. This study is evaluating how well CagriSema helps people with obesity lose weight compared to tirzepatide.
Background
CagriSema is an investigational medicine developed by Novo Nordisk, combining Cagrilintide and Semaglutide. It is being studied for the treatment of obesity. Both semaglutide and tirzepatide are established treatments in the metabolic disease space, with tirzepatide serving as a comparator in this trial.
Trial design
The study, titled "A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight" (NCT06131437), is a Phase 3 trial. It enrolled 809 participants with obesity. The trial is designed to compare the efficacy of CagriSema against tirzepatide in reducing body weight. Participants receive once-weekly subcutaneous injections, with the study medicine gradually increased to a planned dose (2.4 mg CagriSema or 15 mg Tirzepatide).
What this means
The primary completion of this Phase 3 trial marks a significant milestone in the development of CagriSema. While specific efficacy and safety results are not yet available, the completion of data collection brings the scientific and medical communities closer to understanding its potential role in managing obesity, particularly in comparison to an established therapy like tirzepatide. Future release of the trial's key measurements and analyses will provide crucial insights into its comparative effectiveness.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The status for study NCT06131437, titled "A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight," was updated to primary completion on December 8, 2025, on clinicaltrials.gov.